Boehringer Ingelheim's Spiolto Respimat improves quality of life for COPD patients

New data has shown that Spiolto Respimat (tiotropium/olodaterol) from German family-owned pharma major Boehringer Ingelheim provides meaningful quality of life improvements for chronic obstructive pulmonary disease (COPD).

The OTEMTO trials show that Spiolto Respimat provides clinically meaningful >4 point reduction in the St George’s Respiratory Questionnaire (SGRQ) score compared to placebo, which represents a significant improvement in quality of life for COPD patients.

As there is no cure for COPD, improving quality of life is a major goal of treatment, and is measured using the SGRQ. Reduction of the SGRQ score by 4 points or more is deemed clinically meaningful. The OTEMTO trials show that Spiolto Respimat provides a reduction of 4.67 points versus placebo.